Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of vorasidenib versus placebo in residual or recurrent grade 2 IDH-mutant glioma
MOH_2020-09-03_009283Phase 3Not yet recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glioma, astrocytoma and Oligodendroglioma (OG) comparing AG-881 with Placebo (2 arms). Primary endpoint: Safety and efficacy of vorasidenib compared with placebo. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
vorasidenib
03
Conditions
gliomaastrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on MOH_2020-09-03_009283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-03_009283.